Global HPV 2024

Loading

2024 GLOBAL HPV

VACCINATION EDUCATION FORUM

Stand Alone Scientific Symposium Sponsored by MSD

27-28 June 2024 - Marrakech, Morocco

SPEAKERS

Chairs

Melvin Kohn

(USA)

Executive Director MSD Global Medical & Scientific Affairs, HPV Vaccines North Wales, Pennsylvania, USA

Bio

Mel Kohn is currently the Executive Director for HPV Vaccines, Global Medical Affairs, Merck Research Laboratories. He has been in that role since December of 2019. An epidemiologist and a pediatrician, Mel came to Merck in 2013, after a twenty-year career in governmental public health, including work for Oregon’s state health department as the Public Health Director (2008-2013), and State Epidemiologist (1999-2008). As Public Health Director he oversaw a government agency with approximately 750 staff and an annual budget of $250 million, working on a wide range of public health issues, including communicable disease control, chronic disease prevention, maternal and child health, injury prevention and environmental health. In his first role at Merck he was Global Director of Medical Affairs for Adult Vaccines, focused primarily on pneumococcal vaccines. Form 2017-19 he was lead for the EMEAC Regional Vaccines Medical Affairs Team based in Lyon, France. Mel holds a B.A. from Yale in Russian and East European Studies, an M.D. from Harvard, and a Masters of Public Health in Epidemiology from Tulane School of Public Health and Tropical Medicine. He also completed an Epidemic Intelligence Service fellowship at the US Centers for Disease Control and Prevention. He has authored over 40 articles on a variety of public health topics in peer-reviewed journals as well as numerous reports and white papers. He is board-certified in pediatrics and preventive medicine.

Miriam Reuschenbach

(Germany)

Global Director Medical Affairs, HPV Vaccines

Bio

Dr. Miriam Reuschenbach is a Global Director of Medical Affairs for HPV Vaccines at MSD. She studied life sciences in Frankfurt (Germany) and medicine in Heidelberg (Germany), Prague (Czech Republic) and at Duke University (NC, USA). She holds an M.D. (Dr. med.) from the University of Heidelberg. Dr. Reuschenbach had a ten-year academic career as physician-scientist in the HPV field. Before joining MSD in 2016, she led the HPV division of the Clinical Cooperation Unit of the Heidelberg University Hospital and the German Cancer Research Center (DKFZ), a research unit facilitating bench-to-bedside transitions. In that role she oversaw the HPV diagnostics services and was investigator of numerous studies and clinical trials on cervical cancer screening, head and neck cancer biomarkers and novel treatment approaches, including therapeutic vaccines.

Faculty

Nancy Durand

(Canada)

Associate Professor in the Department of Obstetrics and Gynaecology, University of Toronto, Canada

Bio

Dr Durand is an Associate Professor in the Department of Obstetrics and Gynaecology at the University of Toronto in Canada. She received her medical degree from McGill University in Montreal, Canada and completed her residency in Obstetrics and Gynaecology at McGill University. She is on staff at Sunnybrook Health Sciences Centre in Toronto, Canada in the department of Obstetrics and Gynecology specializing in colposcopy. Her principal area of interest is prevention of HPV-related diseases and cancers through HPV vaccination. She is an international key opinion leader and speaker on adult HPV vaccination including males, for the prevention of HPV-related diseases including oropharyngeal cancer.

Anna Giuliano

(USA)

Clinical Research Professor Dorothea Bennett Memorial – American Cancer Society (ACS) Director, Center for Immunization and Infection Research in Cancer (CIIRC) Moffitt Cancer Center Tampa, Florida, USA

Bio

Anna R. Giuliano, PhD, is the founding director of the Center for Immunization and Infection Research in Cancer (CIIRC) at the Moffitt Cancer Center in Tampa, Florida. Dr Giuliano’s career had its inception in the relationship between human papillomavirus (HPV) infections and cervical cancer, and has evolved over the past 30 years to encompass penile, anal, and oral cancers in men, as well as other infectious diseases and their causal relationships with various cancers. Her work has contributed significantly to our understanding of HPV natural history and to HPV vaccine protection against multiple diseases in women and men. An expert in the field of cancer research she has led numerous studies conducted globally. Dr Giuliano was a contributor to the 1999 Institute of Medicine (IOM) report titled The Unequal Burden of Cancer and the 2005 International Agency for Research on Cancer (IARC) report that concluded for the first time that HPV is a cause of multiple cancers in women and men. In 2013, at the American Cancer Society (ACS) 100th anniversary, she was the recipient of the ACS Distinguished Achievement in Cancer Award. In 2018, she was selected for the ACS Clinical Research Professor Award for “Prevention of Infection-Related Cancers.” In 2019, Dr. Giuliano received the American Society of Preventive Oncology (ASPO) Fraumeni Distinguished Lifetime Achievement Award.

Haitham Mirghani

(France)

Professor of Head and Neck Surgery European Hospital Georges Pompidou Paris, France

Bio

Professor of Head and Neck Surgery European Hospital Georges Pompidou Paris, France

Jean-Marie Okwo-Bele

(Switzerland)

Public Health Consultant. Former Director of the Vaccines and Immunization Department, WHO/Geneva, Retired.

Bio

Dr Okwo-Bele provides consultancy and board advisory services on vaccine research and development, vaccine implementation and governance of national immunization programmes. He is a member of the Leadership Coalition Group of the World Federation of Public Health Associations and a member of the WHO Review Committee on the Functioning of the International Health Regulations (2005) during the Covid-19 response. As Director of the WHO Vaccines and Immunization Programme from 2004 to 2017, he led the organization’s vaccine research, vaccine standards and vaccine delivery activities. He enhanced the WHO’s vaccine policy-recommendations, which are referenced for national vaccine adoption and implementation. He previously held several positions including Chief of UNICEF Global Immunization Activities, Head of the WHO Immunization programme in Africa and National Coordinator of the Congo Immunization Programme. In these positions, he led numerous initiatives aimed at expanding childhood immunization as well as disease surveillance and polio eradication. He was involved with the Gavi Alliance operations and Gavi Governance from 2002 to 2017. Author of >30 articles and book chapters, Dr Okwo-Bele received his Medical Degree from the Medical School of the University of Kinshasa, Rep. Dem. of Congo and his Master of Public Health from the Johns Hopkins Blomberg School of Public Health in Baltimore, USA. He received the Rotary Paul Harris Fellow recognition for advancing polio eradication in Africa.

Lily Wu

(MSD-Taiwan)

Regional Director, Medical Affairs, HPV Vaccines, AP

Bio

Lily Wu is the regional director of medical affairs in MSD. She received her medical degree from National Yang Ming University in Taiwan in 2009 and received master of public health in Health Policy and Management from Columbia university in the city of new York. Before joining the industry, she is trained as a family health physician and psychiatrist. She actively engaged in travel medicine and several public health campaigns to raise the public’s awareness on preventive care.

Maria Eugenia Perez

(MSD, Argentina)

Regional Director, Medical Affairs, HPV Vaccines, LATAM

Bio

Maria Eugenia Perez is currently the Regional Director of Medical Affairs for HPV Vaccines for Latin America and the Caribbean Region, Merck Research Laboratories. She has been in that role since March of 2018 after more than 8 years in public health services at the Argentinian National Immunization Program (2008- 2016). During that period she was a member of NITAG on Vaccines Safety at a National level (CONASEVA. 2014-2016). In her first role at MSD she was a medical manager for Vaccines in Argentina, covering all vaccines portfolio. From 2018 onwards she was Lead for the LATAM Regional Vaccines Medical Affairs Team based in Buenos Aires, Argentina. Maria Eugenia graduated from Austral School of Medicine, and completed a fellowship on adult infectious diseases in Argentina. She has authored several articles on a variety of public health topics in peer-reviewed journals as well as numerous reports and white papers. She is member of the Vaccines Commitee at the Argenitinian Infectious Diseases Scientific Society.

Stefano Valente

(Italy)

MD Regional Director Medical Affairs HPV Vaccines Global Medical & Scientific Affairs

Bio

Stefano Valente, MD, Regional Director of Medical Affairs for HPV Vaccines. Europe Stefano earned his medical degree and holds a Diploma in Legal and Forensic Medicine at Sapienza University in Rome. He completed a 3-year residency in General Medicine at S. Camillo Forlanini Hospital, acquiring a Diploma as a General Practitioner. He is currently completing an advanced master course in Clinical Immunology at University of Florence. Since 2017, Stefano has been working at MSD Italy in the role of Therapeutic Area Director for vaccines and spent most of his career in the pharmaceutical company working on the public health field. He has been a sought-after speaker at scientific conferences on vaccinology & vaccine development and is on the faculty of the Master Course in Clinical Development at the University of Parma. Stefano leaves in Rome with his family.

Erika Thompson

(USA)

Associate Professor Department of Population and Community Health School of Public Health University of North Texas Health Science Center Fort Worth, Texas, USA

Bio

Erika Thompson is an Associate Professor in the Department of Biostatistics & Epidemiology in the School of Public Health at the University of North Texas Health Science Center. Her research focuses on HPV vaccination decision-making among adults, school-entry policies, and alternative health care providers and settings for HPV prevention in the United States.

ROSANA RICHTMANN

(Brazil)

Chief of Infectious Diseases Department from Santa Joana Hospital Group, Infectious Disease Specialist, Emilio Ribas Institute of Infectious Diseases Director Brazilian Society of Infectious Disease (Immunization Committee) São Paulo, Brazil

Bio

Graduated from the Faculty of Medical Sciences of Santos, infectious specialized in Hospital for State Civil Servants and a PhD in Epidemiology and Infection Hospital, University of Freiburg, Germany (Freiburg University School at Hospital Epidemiology and Hygiene Department). Chairman of the Hospital Infection Control (CCIH), Hospital Santa Joana and Pro Matre Paulista, Rosana is also medical infectious disease Emilio Ribas Institute of Infectious Diseases since 1988. Current president of the São Paulo Society of Infectious Diseases (SPI) and member of the National Association of Children's Hospitals and Related Institutions (NACHRI) in Atlanta (USA). She has published several national guidelines on hospital infection in neonates, vascular catheter-related infection and several book chapters and has participated as invited to speak at scientific events national, Latin American and international.

Andrea Schilling

(Chile)

Researcher and professor, Center for Clinical Studies, Institute of Science and Innovation in Medicine (ICIM), Clinica Alemana Universidad del Desarrollo Medicine School

Bio

Obstetrician and Gynecologist, specialist in pediatric and adolescent gynecology; university professor and researcher. Areas of expertise, teaching, and research: Contraception, STI Prevention, Human Papillomavirus, and vaccines. (Mostly HPV vaccine).

Dorothy Machalek

(Australia)

Senior Research Fellow Kirby Institute University of New South Wales, Sydney, Australia Honorary Research Fellow for the Centre for Women’s Infectious Disease The Royal Women’s Hospital, Melbourne, Australia

Bio

Dr Dorothy Machalek is a Senior Research Fellow at the Kirby Institute (University of New South Wales, Sydney, Australia) and an Honorary Research Fellow with the Centre for Women’s Infectious Disease at The Royal Women’s Hospital in Melbourne. She holds a Doctorate in epidemiology and a Master of Public Health from the University of New South Wales. Her research focuses on developing and implementing novel public health surveillance systems and evaluating vaccination and screening strategies for HPV prevention. Dr Machalek has led Australia’s national HPV infection monitoring program, funded by the Australian Government, that provided a central mechanism for evaluating the impact of HPV vaccination on HPV infections in Australia. Dr Machalek is also a named investigator on a project evaluating the population impact of one- and two-dose HPV vaccine schedules in South Africa, funded by the Australian National Health and Medical Research Council and the Bill and Melinda Gates Foundation. Her research has informed international guidelines and has led to well-cited publications on the impact of Australia’s HPV prevention policies. She co-leads Australia’s annual cervical cancer elimination national tracking reports.

Ida Ismail-Pratt

(Singapore)

Obstetrician & Gynaecologist SGM Womens Health

Bio

Dr Ida Ismail-Pratt is an Obstetrician & Gynaecologist with an accreditation in colposcopy. Before joining SMG Women’s Health, she was a consultant obstetrician and gynaecologist at the National University Hospital (NUH) and the National Cancer Institute Singapore (NCIS), where she led the gynaecology cancer screening and prevention services and was the lead colposcopist. Dr Ida championed the introduction of HPV DNA testing as an alternative to cervical cancer screening.

Dur-E-Nayab Waheed

(Belgium)

Researcher Centre for Evaluation of Vaccination University of Antwerp, Belgium

Bio

Nayab Waheed is a vaccinologist by training, working as a Researcher at the Centre for Evaluation of Vaccination, University of Antwerp and is the HPV Project Lead for many HPV prevention and control-related projects. Her research is focused on HPV vaccine implementation.

Benda Kithaka

(Kenya)

Executive Director and Founder KILELE Health Association

Bio

A communications and health advocacy specialist, with over 20 years’ experience in partner management, health communications, research, & advocacy. Technical Advisor in Strategy, Donor Relations, Grant Management, Innovation in implementation of WHO Cervical Cancer Elimination Strategy (90-70-90). Also active in policy advocacy, stakeholder and partner relations.

Marcie Fisher-Borne

(USA)

Director, HPV Vaccines Outcomes Research

Bio

Marcie Fisher-Borne joined Merck's HPV Vaccines Outcomes Research team in August 2023, where she currently leads research on HPV implementation and the development and execution of strategies to eliminate HPV-related diseases. With over 25 years of experience, Marcie has expertise in designing, implementing, and evaluating public health interventions and research efforts. Prior to joining MSD, she spent ten years at the American Cancer Society (ACS), where she established and led the Interventions and Implementation Team at the global headquarters. In this role, she oversaw the management and evaluation of a wide range of domestic and global cancer interventions, including the US Vaccinate Adolescents against Cancers program and global cancer prevention teams. Before her time at ACS, Marcie had an academic career with a research focus on infectious disease, health equity, access, and applied research. She taught courses on intervention and implementation research, participatory research methodology, and organizational leadership. Marcie holds a PhD in Social Intervention Research from the University of North Carolina's School of Social Work, and she conducted her doctoral research through the Center for Infectious Disease at the University of North Carolina's School of Medicine. Additionally, she earned her MPH from the UNC Gillings School of Global Health and MSW through UNC’s School of Social Work.

Cathy Ndiaye

(Senegal)

Global Director of HPV Vaccine Programs at PATH

Bio

Dr Cathy Ndiaye is a biologist, epidemiologist, and public health specialist from Senegal. She currently serves as the Global Director of HPV Vaccine Programs at PATH, providing technical guidance and oversight for HPV vaccination implementation programs in several countries in Africa and Asia. She works closely with donors and ministries of health to plan, implement, monitor, and evaluate HPV vaccination programs. Dr Ndiaye led multiple projects related to infectious diseases including HIV, malaria, cholera, typhoid, and Covid-19. She also managed reproductive health programs. She is a member of Gavi’s Global HPV Leadership Subteam and the Coalition to Strengthen the HPV Immunization Community (CHIC).

John Doorbar

(United Kingdom)

Professor, University of Cambridge Cambridge, United Kingdom

Bio

John Doorbar is Professor of Viral Pathogenesis in the Department of Pathology at the University of Cambridge, having worked previously at the National Institute for Medical Research in London. He obtained his PhD in Cancer Studies at Birmingham, and his first degree in Genetics & Microbiology at the University of Leeds. He has devoted much of his career to understanding how the human papillomavirus life cycle is organised, and how interactions between the virus and the infected epithelial cells drive the development of neoplasia and cancer. His current research addresses the mechanisms of lesion formation and regression, and the way that human papillomaviruses modulate epithelial homeostasis to facilitate virus persistence. His research group is focusing on the biology of the cervical transformation zone, and the molecular and cellular processes that make this particular epithelial site vulnerable to HPV infection and neoplastic progression.

Apostolos Stamatiadis

(Greece)

Head of Athens Colorectal Laboratory, Diagnosis and treaatment of anorectal diseses

Bio

Implemented prevention strategies for anal cancer in high-risk groups. Diagnosed and treated anal HPV diseases. Conducted counseling and educational sessions during medical rounds focused on anal cancer prevention and HPV treatment.

Francesco Gesualdo

(Italy)

Paediatrician and researcher at the Bambino Children's Hospital IRCCS, Rome, Italy

Bio

Francesco Gesualdo is a paediatrician and a researcher at the Bambino Children's Hospital IRCCS, Rome, Italy. At present, his main research focus is vaccine communication. He coordinates a multidisciplinary group, including clinicians, social scientists and data-scientists, with the objective of analysing the vaccine discourse on social media in Italy. Among present activities, he is involved in projects dedicated to applying artificial-intelligence based techniques to interpret the natural language of vaccine-related posts on social media. In the past years, he developed an experience in digital epidemiology, studying the use of Twitter for analysing flu epidemics and allergic diseases, he participated in the development of a platform exploiting different web sources for analysing vaccine confidence in Italy, he coordinated the Web Analytics Project for the WHO’s Vaccine Safety Net, and he participated in the development of an online platform dedicated to monitoring vaccine confidence on the web for the European Joint Action on Vaccination. He has participated in the activities of the Istituto Bambino Gesù (a Bambino Gesù Children’s Hospital project dedicated to improving the health literacy of the public on pediatric-related themes), collaborating in the production of contents on the Bambino Gesù Children's Hospital website and of an online magazine dedicated to families, teachers and teenagers. He conducts daily clinical activity with patients as a family paediatrician, with a special focus on breastfeeding and on vaccinations.

Matthys Hendrik Botha

(South Africa)

MBChB, MMed, FCOG, PhD Head of Department of Obstetrics and Gynaecology at Stellenbosch University of and Tygerberg Hospital in South Africa

Bio

Hennie Botha is Head of Department of Obstetrics and Gynaecology at Stellenbosch University of and Tygerberg Hospital in South Africa. His professional career started in a rural hospital in Malawi. Returning to South Africa he specialised in Obstetrics and Gynaecology and then did further training in the field of Gynaecological Oncology in the United Kingdom. He has authored or co-authored many articles in journals and is co-editor of the textbook “Clinical Gynaecology”. His research focus is on cervical cancer prevention and treatment, including in people living with HIV. He collaborates with national and international researchers. He served on the council of the International Gynaecological Cancer Society and is international vice-chair of the HPV Working Group of the AIDS Malignancy Consortium. He is enthusiastic about under-and postgraduate teaching and training and his unit has trained many specialists and sub-specialists in South Africa and other African countries.

Tidiane NDAO

(MSD, Morocco)

Regional Director Medical Affairs, HPV Vaccines, EMEAC

Bio

Physician by training specialized in Public Health and Epidemiology with a strong experience in Clinical Research including phase I/II vaccines trials in the field of Malaria, HIV, Tuberculosis.Robust 11 years’ experience in Medical and Scientific affairs role in Pharma across Middle East and Africa.Currently Regional Director of Medical Affairs for HPV.

Jason YK Chan

(Hong Kong)

Associate Professor Department of Otorhinolaryngology, Head and Neck Surgery Assistant Dean Student development Chinese University of Hong Kong

Bio

Dr Chan graduated from Guy’s, King’s and St Thomas’ School of Medicine in London, followed by specialist training in Otolaryngology, Head and Neck surgery at the Johns Hopkins Medical Institutions with advanced training in Head and Neck surgery, microvascular reconstruction and robotics. He is currently an Associate Professor in the Department of Otorhinolaryngology, Head and Neck Surgery and Assistant Dean (Student development) at The Chinese University of Hong Kong with research interests in head and neck cancers, the microbiome in head and neck cancers and the application of robotics in Head and Neck Surgery.

Edith Morais

(MSD, France)

Global Director of Outcomes Research MSD HPV Vaccines

Bio

Edith Morais is a Global Director of Outcomes Research for HPV Vaccines at MSD. She received her PharmD from the University of Pharmacy in Paris XI (France), and holds a MSc in Public Health and a MSc in Regulatory Affairs. Edith has more than 20 years’ experience in health economics and outcomes research in the pharmaceutical industry and led multiple studies in epidemiology and health economics. Before joining MSD in 2017, she worked in Sanofi and Bristol-Myers Squibb in different regional and global roles in cardiovascular and oncology.

Alex Vorsters

(Belgium)

Senior project coordinator Centre for the Evaluation of Vaccination Faculty of Medicine University of Antwerp, Belgium

Bio

After his studies as Bioengineer at Free University of Brussels, 1989, he followed a postgraduate course on Tropical Veterinary Medicine at Tropical Medicine Institute of Antwerp (ITG). Since 2001 he works as senior project coordinator and researcher at the University of Antwerp within the Centre for the Evaluation of Vaccination. Since then he is involved in several vaccine preventable disease projects including the Viral Hepatitis Prevention board (www.vhpb.org). Since 2015 he coordinates the activities of the Human Papilloma Virus Prevention and Control board (www.hpvboard.org). He got his Phd Medical Sciences in 2016 on detection of HPV DNA in urine and monitoring the impact of HPV vaccination. In 2020 he became Associated Professor and he is currently coordinating a research team that investigates the use of first void urine as a liquid biomarker source: in cervical cancers screening programs, for follow-up of HPV vaccination programs and other genital tract infections in women.

Mona Saraiya

(MSD, USA)

Senior Director MSD Global Medical & Scientific Affairs

Bio

Dr. Saraiya joined MSD in January 2024 as Senior Director Global Medical and Scientific Affair, HPV vaccine. Her previous position was at CDC for 28 years as a medical epidemiologist. Most of her professional activities at CDC were focused on international and domestic cancer control, particularly prevention and control of HPV-related diseases including cervical cancer. She also has experience working on a wide range of other public health issues, including control of TB, HIV, and Zikavirus, as well as maternal and child health, among others. She has worked with a variety of global and US organizations who are important partners in HPV prevention and control. Dr. Saraiya has authored over 250 publications. Dr. Saraiya holds a BA from the University of Chicago, an MD from Rush Medical College, an MPH from Emory School of Public Health. She completed a residency in Preventive Medicine/Public Health, and is board certified by the American College of Preventive Medicine. Dr. Saraiya also is an alumna of the Epidemic Intelligence Service.

Saah Alfred

(MSD, USA)

Executive Director Scientific Affairs MSD

Bio

Alfred received his MD from the University of Maryland, School of Medicine and his MPH from the Johns Hopkins School of Public Health. He is board certified in Internal Medicine, Infectious Diseases and General Preventive Medicine/Epidemiology. He was an EIS officer with CDC and trained and worked at the National Institute of Allergy and Infectious Diseases, NIH for 7 years and at the Johns Hopkins School of Public Health and School of Medicine, where he was on the faculty, for 10 years. While at the NIH, he worked with the FDA and CDC in the research leading to the acellular pertussis vaccine. He also co-founded the Multi-center AIDS Cohort Study (MACS) and was its Principal Investigator at Hopkins until moving to Merck Research Laboratories (MRL). At Hopkins, Al also taught extensively, headed an HIV practice clinic and conducted clinical research into factors influencing HIV infection in women and perinatal transmission in Malawi and Rwanda. His research and clinical activities throughout his career at NIH, Hopkins and MRL have focused on HIV-related research and therapy, tropical medicine, and vaccine development. Alfred joined Infectious Diseases at MRL in 1997 where he supported development or approval of indinavir, efavirenz, caspofungin, ivermectin and was liaison to the Mectizan Expert Committee for the reduction of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis). In 2004, he joined the HPV vaccine development team (Gardasil & Gardasil9) and still works in HPV vaccine development. Additionally, in 2013 Al took over heading the Merck Investigator Studies Program for vaccines.

Agenda

Day 1

Thursday, June 27^th

The webcast will be transmitted Live on:
27 June 2024, 09:00 WEST (UTC +1)

The webcast will be available on demand (for eligible countries only) on:
28 June 2024, 07:00 WEST (UTC +1)
for up to 10 days

09:00

OPENING (15 mins)

09:15

Welcome and introduction

Moderators:
Mel Kohn
Miriam Reuschenbach

09:15

SESSION 1 (40 mins)

09:55

HPV infection and disease biology and epidemiology

Chair:
Dorothy Machalek

↘ Keynote Lectures

09:15 - 09:35 Biology of HPV at different anatomic sites (20 minutes)

John Doorbar

09:35 - 09:55 Global epidemiology of HPV infection and disease (20 minutes)

Dorothy Machalek

09:55

Q&A SESSION 1 (15 mins)

10:10

Q&A (visible during LIVE only)

Dorothy Machalek
John Doorbar

10:10

SESSION 2 (40 mins)

10:50

Overview of HPV vaccine trials: Long-term follow-up and real-world impact and effectiveness

Chair:
Alfred Saah

↘ Keynote Lectures

10:10 - 10:30 Summary of 4vHPV and 9vHPV efficacy and long-term follow-up (20 minutes)

Alfred Saah

10:30 - 10:50 Real-world impact and effectiveness of HPV vaccines (20 minutes)

Dorothy Machalek